Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Jul-Aug;91(4):101580.
doi: 10.1016/j.bjorl.2025.101580. Epub 2025 Apr 3.

New onset migraines after maxillary antrostomy for silent sinus syndrome treated with rimegepant: A rare case report

Aishwarya Aggarwal  1 , Yasemin Akinci  2 , Brian L Gerhardstein  2
Affiliations
Case Reports

New onset migraines after maxillary antrostomy for silent sinus syndrome treated with rimegepant: A rare case report

Aishwarya Aggarwal et al. Braz J Otorhinolaryngol. 2025 Jul-Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare no conflicts of interest.

Similar articles

See all similar articles

References

    1. Numa W.A., Desai U., Gold D.R., Heher K.L., Annino D.J. Silent sinus syndrome: a case presentation and comprehensive review of all 84 reported cases. Ann Otol Rhinol Laryngol. 2005;114:688–694. - PubMed
    1. Pula J.H., Mehta M. Silent sinus syndrome. Curr Opin Ophthalmol. 2014;25:480–484. - PubMed
    1. Thomas R.D., Graham S.M., Carter K.D., Nerad J.A. Management of the orbital floor in silent sinus syndrome. Am J Rhinol. 2003;17:97–100. - PubMed
    1. Karsan N. Vol. 30. 2024. Pathophysiology of migraine; p. 325. (CONTINUUM: lifelong learning in neurology).
    1. Blair H.A. Rimegepant: a review in the acute treatment and preventive treatment of migraine. CNS Drugs. 2023;37:255–265. Erratum in: CNS Drugs. 2023;37:661. - PMC - PubMed

Publication types

LinkOut - more resources